When is patient transfer indicated for the treatment of Chédiak-Higashi syndrome (CHS)?

Updated: Aug 08, 2019
  • Author: Roman J Nowicki, MD, PhD; Chief Editor: Dirk M Elston, MD  more...
  • Print

Increased awareness and the early identification of patients with the potentially lethal form of Chédiak-Higashi syndrome (CHS) convey unique therapeutic and prognostic implications that may improve outcomes. With a high degree of clinical suspicion, these patients should be immediately referred to a tertiary care center and treated by multidisciplinary teams including hematologists, pediatricians, dermatologists, biologists, neurologists, clinical immunologists, and social workers.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!